First U.S. clinical CRISPR data give early safety signal for ex vivo editing

CRISPR cleared its earliest safety hurdle with the first clinical data on the gene editing technology in the U.S., but it's still too early to tell whether that safety signal will persist and apply to other types of CRISPR-based therapies.

In an abstract released in advance of the American Society of Hematology (ASH) meeting on Wednesday, a group from Tmunity Therapeutics Inc. and the University of Pennsylvania unveiled initial clinical data from three multiple myeloma (MM) and myxoid/round cell liposarcoma (MRCL) patients treated with Tmunity's NY-ESO TCR T cell therapy. ...